{"id":"NCT02219490","sponsor":"AbbVie","briefTitle":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","officialTitle":"An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10-30","primaryCompletion":"2021-05-13","completion":"2021-05-13","firstPosted":"2014-08-19","resultsPosted":"2023-04-07","lastUpdate":"2023-04-07"},"enrollment":1596,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C Virus (HCV) Infection Genotype 1"],"interventions":[{"type":"DRUG","name":"ABT-450/r/ABT-267","otherNames":["ABT-450 also known as paritaprevir","ABT-267 also known as ombitasvir","Paritaprevir/ritonavir/ombitasvir also known as Viekirax"]},{"type":"DRUG","name":"ABT-333","otherNames":["ABT-333 also known as dasabuvir","ABT-333 also known as Exviera"]},{"type":"DRUG","name":"Ribavirin (RBV)","otherNames":[]}],"arms":[{"label":"ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to evaluate the effect of treatment with ABT-450 co-formulated with ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333; 3-DAA regimen, with or without ribavirin (RBV) in adults with chronic hepatitis C virus genotype 1 (HCV GT1) infection.","primaryOutcome":{"measure":"All-Cause Death: Time to Event","timeFrame":"At Post-Treatment Weeks 52, 104, 156, 208, and 260","effectByArm":[{"arm":"Participants in Studies M14-222 and M14-423 Who Did Not Achieve SVR12","deltaMin":8.3,"sd":null},{"arm":"Participants in Studies M14-222 and M14-423 Who Achieved SVR12","deltaMin":0.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":187,"countries":["Algeria","Australia","Austria","Belgium","Bulgaria","Canada","Denmark","Finland","France","Germany","Greece","Ireland","Israel","Italy","Mexico","Netherlands","Norway","Poland","Portugal","Romania","Russia","Saudi Arabia","Spain","Sweden","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":40,"n":1596},"commonTop":["FATIGUE","HEADACHE","PRURITUS","NAUSEA","INSOMNIA"]}}